178 related articles for article (PubMed ID: 35087101)
1. Histopathological whole slide image dataset for classification of treatment effectiveness to ovarian cancer.
Wang CW; Chang CC; Khalil MA; Lin YJ; Liou YA; Hsu PC; Lee YC; Wang CH; Chao TK
Sci Data; 2022 Jan; 9(1):25. PubMed ID: 35087101
[TBL] [Abstract][Full Text] [Related]
2. Weakly supervised deep learning for prediction of treatment effectiveness on ovarian cancer from histopathology images.
Wang CW; Chang CC; Lee YC; Lin YJ; Lo SC; Hsu PC; Liou YA; Wang CH; Chao TK
Comput Med Imaging Graph; 2022 Jul; 99():102093. PubMed ID: 35752000
[TBL] [Abstract][Full Text] [Related]
3. Deep Learning Can Predict Bevacizumab Therapeutic Effect and Microsatellite Instability Directly from Histology in Epithelial Ovarian Cancer.
Wang CW; Lee YC; Lin YJ; Firdi NP; Muzakky H; Liu TC; Lai PJ; Wang CH; Wang YC; Yu MH; Wu CH; Chao TK
Lab Invest; 2023 Nov; 103(11):100247. PubMed ID: 37741509
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
5. Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer.
Guler E; Smith DA; Somarouthu B; Gujrathi R; Ramaiya NH; Tirumani SH
Abdom Radiol (NY); 2020 Mar; 45(3):828-841. PubMed ID: 31396642
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
Secord AA; McCollum M; Davidson BA; Broadwater G; Squatrito R; Havrilesky LJ; Gabel AC; Starr MD; Brady JC; Nixon AB; Duska LR
Gynecol Oncol; 2019 Jun; 153(3):555-561. PubMed ID: 30929823
[TBL] [Abstract][Full Text] [Related]
7. [Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa].
Lavoue V; Huchon C; Akladios C; Alfonsi P; Bakrin N; Ballester M; Bendifallah S; Bolze PA; Bonnet F; Bourgin C; Chabbert-Buffet N; Collinet P; Courbiere B; De la Motte Rouge T; Devouassoux-Shisheboran M; Falandry C; Ferron G; Fournier L; Gladieff L; Golfier F; Gouy S; Guyon F; Lambaudie E; Leary A; Lecuru F; Lefrere-Belda MA; Leblanc E; Lemoine A; Narducci F; Ouldamer L; Pautier P; Planchamp F; Pouget N; Ray-Coquard I; Rousset-Jablonski C; Senechal-Davin C; Touboul C; Thomassin-Naggara I; Uzan C; You B; Daraï E
Bull Cancer; 2019 Apr; 106(4):354-370. PubMed ID: 30850152
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
Haunschild CE; Tewari KS
Future Oncol; 2020 Mar; 16(7):225-246. PubMed ID: 31746224
[TBL] [Abstract][Full Text] [Related]
9. First-Line Management of Advanced High-Grade Serous Ovarian Cancer.
Mahmood RD; Morgan RD; Edmondson RJ; Clamp AR; Jayson GC
Curr Oncol Rep; 2020 Jun; 22(6):64. PubMed ID: 32494876
[TBL] [Abstract][Full Text] [Related]
10. Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer.
Selle F; Alexandre J; Prulhière K; Kalbacher E; Ray-Coquard I; Leary A;
Bull Cancer; 2021 Dec; 108(9S1):S5-S12. PubMed ID: 34955161
[TBL] [Abstract][Full Text] [Related]
11. Drug-Resistant Epithelial Ovarian Cancer: Current and Future Perspectives.
Mehrotra M; Phadte P; Shenoy P; Chakraborty S; Gupta S; Ray P
Adv Exp Med Biol; 2024; 1452():65-96. PubMed ID: 38805125
[TBL] [Abstract][Full Text] [Related]
12. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chambers LM; Yao M; Morton M; Gruner M; Chichura A; Horowitz M; Costales AB; Rose PG; Michener CM; Debernardo R
Gynecol Oncol; 2021 May; 161(2):389-395. PubMed ID: 33551202
[TBL] [Abstract][Full Text] [Related]
13. Interferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancer.
Lawal AO; Musekiwa A; Grobler L
Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD009620. PubMed ID: 23740789
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.
Penn CA; Wong MS; Walsh CS
JAMA Netw Open; 2020 Dec; 3(12):e2028620. PubMed ID: 33295974
[TBL] [Abstract][Full Text] [Related]
15. SEOM clinical guideline in ovarian cancer (2020).
Redondo A; Guerra E; Manso L; Martin-Lorente C; Martinez-Garcia J; Perez-Fidalgo JA; Varela MQ; Rubio MJ; Barretina-Ginesta MP; Gonzalez-Martin A
Clin Transl Oncol; 2021 May; 23(5):961-968. PubMed ID: 33515422
[TBL] [Abstract][Full Text] [Related]
16. A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer.
Park J; Eoh KJ; Nam EJ; Kim S; Kim SW; Kim YT; Lee JY
Yonsei Med J; 2020 Apr; 61(4):284-290. PubMed ID: 32233170
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
[No Abstract] [Full Text] [Related]
18. Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
Buechel ME; Enserro D; Burger RA; Brady MF; Wade K; Secord AA; Nixon AB; Mirniaharikandehei S; Liu H; Zheng B; O'Malley DM; Gray H; Tewari KS; Mannel RS; Birrer MJ; Moore KN
Gynecol Oncol; 2021 May; 161(2):382-388. PubMed ID: 33712274
[TBL] [Abstract][Full Text] [Related]
19. Treatment of patients with recurrent epithelial ovarian cancer for whom platinum is still an option.
Buechel M; Herzog TJ; Westin SN; Coleman RL; Monk BJ; Moore KN
Ann Oncol; 2019 May; 30(5):721-732. PubMed ID: 30887020
[TBL] [Abstract][Full Text] [Related]
20. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
